Aytu Biopharma, Inc (AYTU) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2026, Aytu Biopharma reported revenue of $57.6M, down 13.3% from $66.4M the year before. Net income was -$14.3M (a -24.8% net margin). Gross margin was 64.0% and operating margin was -14.4%. Operating activities generated $3.3M of cash, leaving $3.3M of free cash flow. At fiscal year end, Aytu Biopharma held $105.0M in total assets against $69.7M in total liabilities, including $26.3M of cash and equivalents.
Open the full interactive Aytu Biopharma financials → Quarterly statements, key ratios, valuation history and price charts.
Aytu Biopharma Key Stats
| Share Price | $1.99 |
|---|---|
| Market Cap | $24.5M |
| Revenue YoY Growth | -13.3% |
| 52-Week Range | $1.94 – $2.90 |
| Shares Outstanding | 12.3 million (basic, 2026 Q4) |
Aytu Biopharma Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $65.6M | $96.7M | $107.4M | $81.0M | $66.4M | $57.6M |
| Cost of Goods Sold | — | — | $40.8M | $26.4M | $20.6M | $20.8M |
| Gross Profit | $29.2M | $52.3M | $66.6M | $54.6M | $45.8M | $36.8M |
| Operating Income | -$58.9M | -$111.6M | -$17.1M | -$5.3M | -$7.8M | -$8.3M |
| Pre-Tax Income | -$58.0M | -$110.3M | -$17.1M | -$14.1M | -$13.7M | -$14.2M |
| Income Tax | $259,000 | -$110,000 | $0 | $1.8M | $437,000 | $21,000 |
| Net Income | -$58.3M | -$110.2M | -$17.1M | -$15.8M | -$13.6M | -$14.3M |
| Diluted EPS | -$69.60 | -$75.00 | -$5.11 | — | — | — |
Aytu Biopharma Quarterly Results
| 2026 Q1 | 2026 Q2 | 2026 Q3 | 2026 Q4 | |
|---|---|---|---|---|
| Revenue | $13.9M | $15.2M | $12.4M | $16.1M |
| Net Income | $2.0M | -$10.6M | -$5.6M | -$15,000 |
| Diluted EPS | -$0.08 | -$1.05 | -$0.53 | — |
Aytu Biopharma Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $49.6M | $19.4M | $23.0M | $20.0M | $31.0M | $26.3M |
| Current Assets | $105.2M | $59.9M | $72.8M | $61.9M | $79.2M | $61.8M |
| Total Assets | $265.7M | $137.6M | $136.5M | $118.1M | $124.2M | $105.0M |
| Current Liabilities | $109.4M | $64.4M | $69.0M | $62.2M | $63.1M | $54.7M |
| Total Long-Term Debt | $16.8M | $14.4M | $14.8M | $12.7M | $12.8M | $11.0M |
| Total Liabilities | $128.1M | $91.5M | $97.1M | $90.4M | $105.2M | $69.7M |
| Shareholders' Equity | $137.6M | $46.1M | $39.4M | $27.7M | $19.0M | $35.3M |
Aytu Biopharma Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$26.0M | -$28.8M | -$5.1M | -$1.4M | -$1.9M | $3.3M |
| Cash From Investing | -$2.8M | -$3.2M | -$117,000 | -$329,000 | -$2.6M | -$29,000 |
| Cash From Financing | $30.3M | $1.5M | $8.9M | -$1.3M | $15.4M | -$7.9M |
| Free Cash Flow | -$26.0M | -$28.8M | -$5.1M | — | -$2.2M | $3.3M |
Figures from Aytu Biopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Aytu Biopharma financials page for every line item.
Aytu Biopharma Company Profile
| Ticker | AYTU |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Denver, Colorado |
| Incorporated in | Delaware |
| Fiscal Year End | June 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001385818 |
Frequently Asked Questions
What was Aytu Biopharma's revenue in fiscal 2026?
Aytu Biopharma (AYTU) reported revenue of $57.6M for fiscal 2026.
What is Aytu Biopharma's annual revenue history?
Aytu Biopharma's annual revenue by fiscal year: 2021: $65.6M; 2022: $96.7M; 2023: $107.4M; 2024: $81.0M; 2025: $66.4M; 2026: $57.6M.
What was Aytu Biopharma's net income in fiscal 2026?
Aytu Biopharma reported net income of -$14.3M for fiscal 2026.
How much free cash flow did Aytu Biopharma generate in fiscal 2026?
Aytu Biopharma generated $3.3M of free cash flow in fiscal 2026.
What was Aytu Biopharma's revenue last quarter?
In its most recent reported quarter (2026 Q4), Aytu Biopharma reported revenue of $16.1M.
How much debt does Aytu Biopharma have?
Aytu Biopharma reported $11.0M of long-term debt, including the current portion, at the end of fiscal 2026.
How many shares of Aytu Biopharma are outstanding?
Aytu Biopharma reported a weighted average of 12.3 million basic shares outstanding in 2026 Q4.
What is Aytu Biopharma's market cap?
Based on its latest closing price, Aytu Biopharma (AYTU) has a market capitalization of about $24.5M.
When does Aytu Biopharma's fiscal year end?
Aytu Biopharma's fiscal year end, as registered with the SEC, is June 30.
Where is Aytu Biopharma headquartered?
Aytu Biopharma lists its business address in Denver, Colorado in its SEC filings.